Montefiore Einstein Cancer Center Receives $10 Million Grant for Breast Cancer Research

On November 3, 2026, the Montefiore Einstein Comprehensive Cancer Center (MECCC) announced a significant milestone in cancer research: a multi-institutional team led by Dr. Julio A. Aguirre-Ghiso has secured a $10 million grant from the National Cancer Institute (NCI). This funding will support a five-year research initiative focusing on the complexities surrounding breast cancer relapse.

Breast cancer remains one of the leading causes of cancer-related mortality worldwide, claiming approximately 685,000 lives annually. Much of this mortality is attributed to the recurrence of the disease in different organs, often many years after initial treatment, such as surgery, chemotherapy, or radiation. Unbeknownst to many, even small, seemingly non-threatening tumors can lead to the development of micrometastases—tiny clusters of cancer cells that can evade detection yet remain in the body following treatment. These cells can go into a dormant state for years, only to later reappear and trigger a resurgence of cancer.

Investigating Cancer Dormancy

The primary focus of the new research is the phenomenon of cancer cell dormancy. This area of cancer biology has long been a mystery, particularly when it comes to understanding the properties of cancer cells that survive aggressive therapies by entering a dormant phase. Dr. Aguirre-Ghiso articulates a visionary approach, stating, "For two decades, we have been pioneering a new era of cancer research aimed at developing proactive strategies that can prevent recurrence and enhance long-term remission rates."

The research will utilize clinical data and tissue samples from patients diagnosed with ductal carcinoma in situ (DCIS)—a non-invasive breast cancer variant—for analysis. Key questions include what characteristics are linked to the early spread of cancer and how these characteristics might lead to future relapses.

A Collaborative Approach

This multidisciplinary project is remarkable for its collaborative nature, uniting researchers from varying backgrounds, including cancer biology, pathology, epidemiology, and bioinformatics. By merging patient data with laboratory findings and advanced imaging techniques, Dr. Aguirre-Ghiso and his team aim to uncover the subtle cues that signal why certain breast cancer cells disseminate early and later reemerge.

Co-leading this research effort alongside Dr. Aguirre-Ghiso are experts from prestigious institutions: Dr. Christina Curtis from Stanford University will focus on molecular signaling aspects, while Dr. Jianlong Wang from Columbia University will delve into the cellular interactions that facilitate cancer spread. Another crucial piece of the puzzle involves studying macrophages—immune cells implicated in aiding cancer cell dissemination. Dr. David R. Entenberg from MECCC is collaborating on this front with Dr. Miriam Merad of Mount Sinai Health System, aiming to discern how different macrophage populations impact the spread of breast cancer.

In addition, expertise in pathology provided by Dr. Maja H. Oktay at Einstein will be pivotal for identifying biomarkers that correlate with recurrence. The research team also comprises statisticians and bioinformaticians who will analyze genetic and clinical data to better predict cancer recurrence outcomes.

Significance for Future Treatments

The study titled "Mechanisms of Early Breast Cancer Local and Distant Relapse" represents a concerted effort not only to understand the biological basis of cancer recurrence but also to identify patients at the highest risk. The aim is to find novel ways to intervene before cancer has a chance to return. Employing cutting-edge imaging technologies, researchers will track the trajectory of cancer cells in real-time, potentially transforming the landscape of breast cancer treatment.

The ongoing dedication of MECCC in the fight against cancer, particularly in underserved communities within the Bronx, underscores their mission to ensure equitable access to groundbreaking cancer research and clinical trials. With new insights from this research, the ultimate goal is to reduce the breast cancer burden, equipping healthcare professionals with the tools needed to combat this pervasive disease effectively.